Integration of genomic technologies for accelerated cancer drug development.

New technologies have greatly increased the scientist's ability to investigate complex molecular interactions that occur in cancer development and to identify genetic alterations and drug targets. However, these new capabilities have not accelerated drug development efforts; rather, they may be contributing to increased research and development costs because the large number of new drug targets discovered through genomics need to be investigated in great detail to characterize their putative functional involvement in the disease process. One solution to this bottleneck in functional analysis is the use of high-throughput technologies to produce efficient processes that can rapidly handle the large flood of information at every stage of disease. This review examines the use of new and emerging DNA, tissue, and live-cell transfection microarray technologies that can be used to discover, validate, and translate information resulting from the completion of the Human Genome Project.

[1]  M. Bittner,et al.  Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. , 2002, Cancer cell.

[2]  Yudong D. He,et al.  Functional Discovery via a Compendium of Expression Profiles , 2000, Cell.

[3]  M. Vidal,et al.  Prospects for drug screening using the reverse two-hybrid system. , 1999, Trends in biotechnology.

[4]  D. Sabatini,et al.  Microarrays of cells expressing defined cDNAs , 2001, Nature.

[5]  F. Bertucci,et al.  Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. , 2002, The American journal of pathology.

[6]  P. Brown,et al.  Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Colin Campbell,et al.  Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays , 2003, Oncogene.

[8]  D. Botstein,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[9]  Ajay N. Jain,et al.  Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. , 2002, Cancer research.

[10]  H. Dietz,et al.  A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition , 2001, Nature Biotechnology.

[11]  K Sivakumar,et al.  General nonlinear framework for the analysis of gene interaction via multivariate expression arrays. , 2000, Journal of biomedical optics.

[12]  O. Kallioniemi,et al.  From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. , 2001, Seminars in cancer biology.

[13]  Ash A. Alizadeh,et al.  Genome-wide analysis of DNA copy-number changes using cDNA microarrays , 1999, Nature Genetics.

[14]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[15]  D. Pinkel,et al.  Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors , 2022 .

[16]  Colin Campbell,et al.  Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones , 2002, Genes, chromosomes & cancer.

[17]  P. Brown,et al.  Exploring the metabolic and genetic control of gene expression on a genomic scale. , 1997, Science.

[18]  Eric S. Lander,et al.  Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays , 2000, Nature Biotechnology.

[19]  Y. Chen,et al.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. , 2000, Journal of the National Cancer Institute.

[20]  J. Sambrook,et al.  DNA Microarrays: A Molecular Cloning Manual , 2002 .

[21]  E. Dougherty,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[22]  Michael L. Bittner,et al.  Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  H. Dietz,et al.  Nonsense-mediated mRNA decay in health and disease. , 1999, Human molecular genetics.

[24]  Spyro Mousses,et al.  Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling , 2001, Oncogene.

[25]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[26]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[28]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[29]  A. Fire,et al.  Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Ringnér,et al.  Impact of DNA amplification on gene expression patterns in breast cancer. , 2002, Cancer research.

[31]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[32]  J. Herman,et al.  Alterations in DNA methylation: a fundamental aspect of neoplasia. , 1998, Advances in cancer research.

[33]  Teruhiko Yoshida,et al.  Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH. , 2002, Biochemical and biophysical research communications.

[34]  Yusuke Nakamura,et al.  Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. , 2002, Molecular cancer therapeutics.

[35]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[36]  A. Hui,et al.  Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. , 2002, International journal of oncology.

[37]  Joe W. Gray,et al.  Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas , 2001, Nature Genetics.

[38]  N. Sampas,et al.  Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.

[39]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[40]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[41]  R. Losson,et al.  Interference of nonsense mutations with eukaryotic messenger RNA stability. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Torben F. Ørntoft,et al.  Identifying distinct classes of bladder carcinoma using microarrays , 2003, Nature Genetics.

[43]  Allan Bradley,et al.  Genome-wide detection of chromosomal imbalances in tumors using BAC microarrays , 2002, Nature Biotechnology.

[44]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[46]  D. Albertson.  Profiling Breast Cancer by Array CGH , 2003, Breast Cancer Research and Treatment.

[47]  Wei Zhang,et al.  Molecular Classification of Human Diffuse Gliomas by Multidimensional Scaling Analysis of Gene Expression Profiles Parallels Morphology‐Based Classification, Correlates with Survival, and Reveals Clinically‐Relevant Novel Glioma Subsets , 2002, Brain pathology.

[48]  Carl Virtanen,et al.  Integrated classification of lung tumors and cell lines by expression profiling , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  H. Melhus,et al.  A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. , 2003, Pharmacogenetics.

[50]  Spyro Mousses,et al.  Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. , 2002, Cancer research.

[51]  P. Brown,et al.  Drug target validation and identification of secondary drug target effects using DNA microarrays , 1998, Nature Medicine.

[52]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.